Viewing Study NCT06644768

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:53 PM
Ignite Modification Date: 2026-01-04 @ 11:45 AM
Study NCT ID: NCT06644768
Status: RECRUITING
Last Update Posted: 2025-10-09
First Post: 2024-10-01
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Sponsor: Daiichi Sankyo
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
None Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NSCLC View
None Tumor View
None pembrolizumab View
None valemetostat tosylate View
None DS-3201b View
None Immune checkpoint inhibitor View
None Programmed Cell Death 1 Ligand 1 View
None MK-3475 View